Assessing the impact of the CMS price transparency rule on patients with prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

“It’s the prices, stupid,” Uwe E. Reinhardt and authors famously wrote in their 2003 article describing the cause of high health care spending in the United States.1 Since then, multiple large analyses have confirmed that the prices of labor and goods, including pharmaceuticals and administrative costs, more so than differences in utilization, are the primary drivers of high health care spending.2,3

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Ankit Agarwal, MD, MBA
Resident physician, Department of Radiation Oncology, University of North Carolina at Chapel Hill
Trevor J. Royce, MD, MS, MPH
Assistant professor, Department of Radiation Oncology, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Table of Contents

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 
Ankit Agarwal, MD, MBA
Resident physician, Department of Radiation Oncology, University of North Carolina at Chapel Hill
Trevor J. Royce, MD, MS, MPH
Assistant professor, Department of Radiation Oncology, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login